NASDAQ
10.10.25 | 21:59
70,12 US-Dollar
0,00 % 0,00
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Tarsus targets 95,000-100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum | 2 | Seeking Alpha | ||
| 06.08. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | 392 | GlobeNewswire (Europe) | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| 06.08. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.08. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.06. | Tarsus Pharmaceuticals auf Goldman Sachs Konferenz: Fokus auf strategisches Wachstum | 3 | Investing.com Deutsch | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 02.06. | Oppenheimer assumes Tarsus stock at outperform on strong sales | 1 | Investing.com | ||
| 27.05. | Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 2 | Benzinga.com | ||
| 27.05. | H.C. Wainwright sets $72 target for Tarsus stock with Buy rating | 2 | Investing.com | ||
| 06.05. | 6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know | 2 | Benzinga.com | ||
| 02.05. | Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign | 1 | Seeking Alpha | ||
| 01.05. | Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.64, revenue of $78.3M | 3 | Seeking Alpha | ||
| 01.05. | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | 756 | GlobeNewswire (Europe) | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| 01.05. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 01.05. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | An Overview of Tarsus Pharmaceuticals' Earnings | 2 | Benzinga.com | ||
| 24.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | 1 | GlobeNewswire (USA) | ||
| 22.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | 1 | GlobeNewswire (USA) | ||
| 13.01. | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | 607 | GlobeNewswire (Europe) | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,690 | -0,12 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| MODERNA | 23,405 | +1,92 % | Moderna, Inc.: Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress | mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,425 | +1,87 % | Why Shares in Viking Therapeutics Surged This Week | ||
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings sichert sich neue Finanzierung und Option auf bis zu 5 Mio. US-Dollar | ||
| KUROS BIOSCIENCES | 31,340 | +1,10 % | Kuros Biosciences AG: Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 | Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025
Schlieren (Zürich), Switzerland - September 30, 2025 - Kuros Biosciences ("Kuros" or the "Company"), a leader... ► Artikel lesen | |
| ABIVAX | 84,10 | +5,12 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| RELIEF THERAPEUTICS | 3,485 | -4,65 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
08-Oct-2025... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,883 | +4,36 % | Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? | ||
| DENALI THERAPEUTICS | 13,520 | +2,15 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,900 | +0,69 % | CytomX: Führt CX-2051 zur Übernahme? | Die Aktie des US-Biotechunternehmens CytomX Therapeutics, einer unserer immer wieder äußerst lukrativen Dauerbrenner in der Community, hat in diesem Jahr deutlich an Dynamik gewonnen. Nach überzeugenden... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,017 | +3,18 % | Leerink Partners lowers Rocket Pharmaceuticals stock price target on BLA withdrawal | ||
| SYNDAX PHARMACEUTICALS | 14,400 | +3,60 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October... ► Artikel lesen | |
| ASCENDIS PHARMA | 181,00 | +0,56 % | Achondroplasie-Therapie: Ascendis Pharma reicht Zulassungsantrag in der EU ein | ||
| JASPER THERAPEUTICS | 2,395 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants | REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a clinical-stage biotechnology company focused on development of briquilimab, a novel... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 3,240 | 0,00 % | XFRA 2QV: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCHEMOMAB THER. ADR/20... ► Artikel lesen |
TARSUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 70,12 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.